Sigachi Industries FY25 revenue surges 25%, EBITDA 46%

Newly commissioned MCC in Jhagadia and Dahej and CCS project expansions will unlock an additional 8,800 MTPA, fuelling year-over-year revenue gains of 20%-30% in excipients

Pfizer inks $1.25 billion cancer antibody licensing deal with China's 3SBio

3SBio will receive an upfront payment of $1.25 billion and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $4.8 billion

Morepen Board proposed dividend after 23 years

Scores highest PAT of Rs. 118 crore in FY25

Morepen to launch new fatty lever drug ‘Resmetirom’

Merck to acquire US Biopharma firm SpringWorks Therapeutics for enterprise value of $3.4 billion

Planned acquisition will strengthen the presence of Merck Healthcare in the United States and expand reach of SpringWorks’ therapeutic innovations to more patients with rare tumors worldwide

Suven Pharmaceuticals get final approval to amalgamate Cohance Lifesciences

The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations

Pfizer advances vision for future of cancer care at ASCO 2025 Annual Meeting

Multiple studies show the combination potential of vedotin antibody-drug conjugates (ADCs) with pembrolizumab, including the first Phase 1 data in thoracic cancers for two first-in-class ADCs

Lyka Labs secures Indian patent for Pregabalin Gel 8%

Pregabalin Gel 8% is a novel topical solution for diabetic neuropathic pain

Siemens acquires Dotmatics for $5.1 billion to strengthen Life Sciences portfolio

Increases Siemens’ industrial software total addressable market by $11 billion; aligns with strategic goal to accelerate customer innovation across industries

Bio-Thera & Dr Reddy’s execute commercialization pact for biosimilars Stelara & Simponi for SE Asia

Bio-Thera will maintain responsibility for development, manufacturing, and supply of BAT2206 and BAT2506